The history of Sildenafil presents a complex picture for shareholders. While the initial introduction generated substantial gains, the end of its patent opened the floodgates to generic competitors, dramatically eroding market share. This creates a unique risk for drug manufacturers banking on similar blockbuster medications, suggesting that a care

The history of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in income, its intellectual property lapse created a flood of generic competition , significantly eroding its market share . While specific pharmaceutical companies may seek to capitalize on similar c